Prophylactic effects of arketamine, but not hallucinogenic psychedelic DOI nor non-hallucinogenic psychedelic analog lisuride, in lipopolysaccharide-treated mice and mice exposed to chronic restrain stress

• Published in: Pharmacology, biochemistry and behavior biochemistry and behavior, 2023-12, Vol.233, p.173659, Article 173659
• Main Authors: Liu, Guilin, Ma, Li, Qu, Youge, Wan, Xiayun, Xu, Dan, Zhao, Mingming, Murayama, Rumi, Hashimoto, Kenji
• Format: Article
• Language: English
• Subjects: Animals; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Depression - drug therapy; Depression - metabolism; Depression - prevention & control; Hallucinogens - pharmacology; Humans; Lipopolysaccharides - pharmacology; Lisuride; Male; Mice; Serotonin - metabolism; Sucrose
• ISSN: 0091-3057; 1873-5177; 1873-5177
• DOI: 10.1016/j.pbb.2023.173659

Anesthetic ketamine and classical psychedelics that act as 5-hydroxytryptamine-2A receptor (5-HT R) agonists demonstrated rapid and sustained antidepressant actions in patients with treatment-resistant depression. The new antidepressant arketamine is reported to cause long-lasting prophylactic effects in lipopolysaccharide (LPS)-treated mice and mice exposed to chronic restrain stress (CRS). However, no study has compared the prophylactic effects of DOI (2,5-dimethoxy-4-iodoamphetamine: a hallucinogenic psychedelic drug with potent 5-HT R agonism), lisuride (non-hallucinogenic psychedelic analog with 5-HT R and 5-HT R agonism), and arketamine on depression-like behaviors in mice. Saline (10 ml/kg), DOI (2.0 or 4.0 mg/kg), lisuride (1.0 or 2.0 mg/kg), or arketamine (10 mg/kg) was administered intraperitoneally (i.p.) to male mice 6 days before administration of LPS (1.0 mg/kg). Pretreatment with aketamine, but not DOI and lisuride, significantly ameliorated body weight loss, splenomegaly, the increased immobility time of forced swimming test (FST), and the decreased expression of PSD-95 in the prefrontal cortex (PFC) of LPS-treated mice. In another test, male mice received the same treatment one day before CRS (7 days). Pretreatment with aketamine, but not DOI and lisuride, significantly ameliorated the increased FST immobility time, the reduced sucrose preference in the sucrose preference test, and the decreased expression of PSD-95 in the PFC of CRS-exposed mice. These findings suggest that, unlike to arketamine, both DOI and lisuride did not exhibit long-lasting prophylactic effects in mouse models of depression.